Previous 10 | Next 10 |
Gainers: PING +13.3% . SNDL +12.2% . PRSP +8.3% . PSNL +7.5% . TGP +6.5% . More news on: Ping Identity Holding Corp., Sundial Growers Inc., Perspecta Inc., Stocks on the move, Read more ...
NextCure is down after trial data NextCure ( NXTC ) is a recently IPO-ed small cap that has come under my radar mainly because of its tremendous rise after the IPO lock-up period. That is a very good sign; it basically shows the confidence insiders must have on the stock, since they did not ...
NEW YORK, NY / ACCESSWIRE / November 13, 2019 / Kadmon Holdings, Inc. (NYSE: KDMN) ("Kadmon") today announced its intention to offer and sell shares of its common stock in a public offering pursuant to its existing shelf registration statement. Kadmon also intends to grant the underwriters a...
Penny stocks are perhaps one of the most popular classes of stocks among investors. The simple reason for that is the possibility of making enormous returns from a small investment. However, it should be noted that penny stocks are inherently volatile. So, investors need to be quite careful ...
November 13, 2019 Palm Beach, FL –November 13, 2019 – For decades researchers have been trying to find newer and more effective ways to fight cancer cells. Today much research is focused on attacking the cancerous cells growth. The reasoning is that denying these cells e...
Shares of Kadmon Holdings (NYSE: KDMN) , a biopharmaceutical company, jumped by as much as 25.1% Tuesday morning in response to a positive result from a pivotal study of its most valuable treatment candidate, KD025. Enthusiasm for the stock has faded somewhat during the afternoon, a...
Craft Brew Alliance (NASDAQ: BREW ) +122% on buyout . More news on: Craft Brew Alliance, Inc., Kadmon Holdings, Inc., Ladenburg Thalmann Financial Services Inc., Stocks on the move, Read more ...
Gainers: BREW +122.2% . KDMN +18.1% . ICUI +11.1% . APYX +6.8% . GO +6.6% . More news on: Craft Brew Alliance, Inc., Kadmon Holdings, Inc., ICU Medical, Inc., Stocks on the move, Read more ...
A pivotal Phase 2 study evaluating Kadmon Holdings' (NYSE: KDMN ) lead candidate KD025 in patients with chronic graft-vs-host disease (cGvHD) who had received at least two prior lines of therapy met the primary endpoint at the interim analysis, two months after the completion of enrollme...
KD025 Achieved ORRs of 64% with KD025 200 mg QD and 67% with KD025 200 mg BID Conference Call Today at 5:00 p.m. Eastern Time NEW YORK / ACCESSWIRE / November 11, 2019 / Kadmon Holdings, Inc. (NYSE: KDMN) today announced positive topline results from the planned interim analysis...
News, Short Squeeze, Breakout and More Instantly...
- REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets are now commercially available for shipment to prescribed patients in the United States - - Execution of strategic launch strategy underway; Third quarter REZUROCK net sales $12.2 million - - Sanofi acquisition of Kadm...
NEW YORK, NY / ACCESSWIRE / October 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced it will present data from the ongoing Phase 1 clinical trial of KD033, its anti-PD-L1/IL-15 fusion protein, in patients with metastatic or locally advanced solid tumors, in addition to other IL-...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Kadmon Holdings, Inc. Skyrockets Amid Entering Definitive Merger Agreement with Sanofi Kadmon Holdings, Inc. (NASDAQ: KDMN) surged 73% in premarket trading after entering...